Haleon (LSE:HLN) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Haleon Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Haleon's Capital Expenditure for the three months ended in Mar. 2024 was £0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was £655.00 Mil.

Hence, Haleon's Capex-to-Operating-Income for the three months ended in Mar. 2024 was 0.00.

Haleon Capex-to-Operating-Income Historical Data

The historical data trend for Haleon's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Capex-to-Operating-Income Chart

Haleon Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

0.27

0.20

0.18

0.17

Haleon Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Haleon's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haleon's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Haleon's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Haleon's Capex-to-Operating-Income falls into.

Haleon Capex-to-Operating-Income Calculation

Haleon's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-336)	/	1996
	=	0.17

Haleon's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	655
	=	0.00

Haleon (LSE:HLN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Haleon Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Haleon's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon (LSE:HLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (LSE:HLN) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

HLNCF:USA HLN:USA HLN1:Mexico HLNl:UK H6D0:Germany

Address

The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY

Website

https://www.haleon.com

Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.